Date: 2014-09-10
Type of information: R&D agreement
Compound: auristatin-based antibody-drug conjugate (ADC) technology, HuMax®-AXL
Company: Genmab (Denmark) Seattle Genetics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: HuMax-AXL-ADC is an antibody-drug conjugate (ADC) combining a high affinity human monoclonal antibody against AXL with Seattle Genetics\' clinically validated cytotoxic drug. AXL is a signaling molecule involved in multiple processes of tumor development and progression. The target molecule is highly expressed on a variety of solid cancers.
Disease: solid tumors
Details: * On September 10, 2014, Seattle Genetics and Genmab announced that the companies have entered into an additional antibody-drug conjugate (ADC) collaboration. Genmab has acquired exclusive rights to utilize Seattle Genetics\' auristatin-based ADC technology with HuMax®-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers.
Seattle Genetics and Genmab entered into an ADC collaboration for HuMax-TF-ADC in September 2010. HuMax-TF-ADC, targeting the Tissue Factor antigen, is in a Phase I trial for solid tumors. Seattle Genetics has the right to exercise a co-development option to share all future costs and profits for HuMax-TF-ADC at the end of Phase I.
Financial terms: Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics\' auristatin-based ADC technology with Genmab\'s HuMax®-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmab\'s initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization.
Latest news:
